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The  canine  cytokine  IL-31  induces  pruritus  in  dogs  and  can  be  detected  in  dogs  with  atopic
dermatitis;  however  very  little  is  understood  around  its  interactions  with  speciﬁc  canine
cells. We  hypothesize  that  IL-31  is  involved  in  the  progression  of  allergic  skin  disease  by
coordinating  the interaction  between  the  immune  system  with  skin  and  neuronal  systems.
The goal  of  the  following  work  was  to identify  cells  that  produce  IL-31  as  well  as  cells
that  may  respond  to  this  cytokine.  Peripheral  blood  mononuclear  cells  (PBMCs)  were  col-
lected from  naïve  and  house  dust  mite  (HDM)  allergen-sensitized  beagle  dogs  and  used
for ex  vivo  characterization  of  cytokine  production  assessed  using  ELISpot  and  quantitative
immunoassay.  Sensitization  to HDM  allergen  induced  a  T-helper  type  2  (Th2)  cell  phenotype
characterized  by an  increase  in  the production  of  IL-4 protein.  Interestingly,  repeated  aller-
gen  challenge  over  time  also  resulted  in  an increase  in  IFN-.  Further  evaluation  showed
that  co-stimulation  of  Th2 polarized  cells  with  antigen  and  the  bacterial  component  Staphy-
lococcus enterotoxin  B  (SEB)  produced  higher  levels  of  IL-31  compared  to either  stimulant
alone.  Production  of  IL-31  when  PBMCs  were  stimulated  by T  cell  mitogens  suggests  T cells
as  a source  of IL-31.  Quantitative  real-time  PCR  was  utilized  to determine  expression  of the
IL-31  receptor  alpha  chain  in  canine  cell  lines  and  tissue.  Canine  monocytic  cells, keratino-
cytes,  and  dorsal  root ganglia  were  shown  to  express  the  IL-31  receptor  alpha  chain  mRNA.
In a multifaceted  disease  such  as  canine  atopic  dermatitis,  the  combination  of  Th2  polariza-
tion and microbial  presence  may  lead  to  IL-31  mediated  effects  driving  inﬂammation  and
pruritus  by immune  cells,  keratinocytes,  and  direct  neuronal  stimulation.
he Aut© 2013 T
. Introduction
Canine atopic dermatitis (AD) is a common allergic skin
isease characterized by pruritus and inﬂammation. AD
s genetically pre-disposed and results from dysfunction
n the skin and immune system (DeBoer, 2004). Skin
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abnormalities in the ultrastructure, stratum corneum, and
barrier proteins have been identiﬁed in dogs with clinical
disease (Olivry, 2011). Imbalance in the immune response
characterized by increased levels of T helper type 2 (Th2)
cytokines including IL-4, IL-5, and IL-13 (Hayashiya et al.,
2002; Maeda et al., 2009; Nuttall et al., 2002b; Schlotter
et al., 2011) is also associated with AD. The role for the
Th1 cytokine IFN- has been less clear although it has
been detected in both lesional skin and peripheral blood
mononuclear cells (PBMCs) from dogs with AD (Nuttall
Open access under CC BY-NC-ND license.et al., 2002a; Stehle et al., 2010). Interaction between
the skin and immune system are highlighted in studies
demonstrating that canine keratinocytes can respond to
both cytokine and allergen challenge with the production
-NC-ND license.
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of inﬂammatory mediators such as GM-CSF (Kimura et al.,
2012; Maeda et al., 2009).
IL-31 is a relatively novel cytokine that when over-
expressed in transgenic mice leads to the recapitulation of
many of the hallmark signs of AD including inﬂammatory
inﬁltrate in the skin and pruritus (Dillon et al., 2004). In
human AD, IL-31 levels correlate with disease severity and
have been shown to be increased in both the skin and serum
(Ezzat et al., 2011; Kim et al., 2011b), and reports suggest
that Th2 cells and skin-homing T cells are sources of IL-
31 (Bilsborough et al., 2006; Gutzmer et al., 2009). Initial
efforts to clone canine IL-31 resulted in the detection of IL-
31 mRNA in mitogen-activated PBMCs and various tissues
(Mizuno et al., 2009). Recently canine IL-31 was shown to
rapidly induce pruritus when directly administered to dogs
(Gonzales et al., 2013). In addition IL-31 was detected in
the serum of dogs with atopic dermatitis but not in healthy
controls (Gonzales et al., 2013).
IL-31 receptors have been detected on a variety of
cell types including primary human CD1c(+) cells, human
monocyte-derived dentritic cells, human macrophages,
keratinocytes, eosinophils, mast cells, bronchial epithelia,
colonic subepithelial myoﬁbroblasts, and human as well as
rat dorsal root ganglion tissue (Cornelissen et al., 2012).
Some investigators have also reported that IL-31 receptor
expression is induced by the pro-inﬂammatory cytokine
IFN- (Diveu et al., 2003; Heise et al., 2009; Kasraie et al.,
2011), suggesting that the IL-31 cytokine and its receptor
system may  provide positive feedback to drive inﬂam-
mation in non-immune tissues to lead to conditions like
inﬂammatory skin disease.
The objective of the following work was to test the
hypothesis that IL-31 is involved in the propagation of
atopic disease in dogs via coordinating an interaction
between the immune system, skin and neuronal systems.
To address this, we investigated the polarization of immune
cells before and after allergen sensitization as well as dur-
ing allergen re-challenge over time and characterized IL-31
production. In order to determine cell types that may  be
targets of IL-31 activity, we tested monocytic cells, kerati-
nocytes, and neuronal tissue for mRNA expression of the
IL-31 receptor alpha chain.
2. Materials and methods
2.1. Animals
All animal procedures were approved by the Insti-
tutional Animal Care and Use Committee (Zoetis, Inc.,
Kalamazoo, MI,  USA) and were performed in compliance
with the Animal Welfare Act, Regulations, 9 CFR Parts
1, 2 and 3, and with the Guide for the Care and Use
of Laboratory Animals Eighth Edition, issued by the US
Institute for Laboratory Animal Research Commission of
Life Sciences (National Academies Press, Washington, DC,
2011). Purpose-bred beagle dogs (Marshall BioResources,
North Rose, NY, USA) were used for all experimental
work. Samples were collected from normal or house dust
mite (HDM)-sensitized dogs. In brief, HDM-sensitization
consisted of a series of three injections of antigen (10 g,
Greer Laboratories, Lenoir, NC, USA) and Rehydragelnd Immunopathology 157 (2014) 42– 48 43
(0.1 mL,  Reheis Inc, Berkley Heights, NJ, USA) at two week
intervals. The same allergen formulation was  used for any
re-exposures subsequent to the initial sensitization. Sensi-
tization was  conﬁrmed by intradermal skin testing. Whole
blood samples were collected by venopuncture. Dorsal root
ganglia (DRG) tissue samples were collected from non-
HDM-sensitized dogs that were euthanized for purposes
unrelated to this study. Immediately post-mortem, tissue
was snap-frozen and stored at −80 ◦C until RNA processing
was completed at a later time.
2.2. Cell isolation, culture, and treatment
Fresh whole blood samples were collected into lithium
heparin tubes, diluted with PBS and overlayed onto pre-
pared AccuSpin tubes (Sigma–Aldrich, St. Louis, MO,  USA)
for PBMC isolation. Samples were spun at 800 × g for
30 min  at room temperature with no brake, collected,
washed twice and resuspended in culture media. Mono-
cytic cells (DH82, ATCC, Manassas, VA, USA) were grown in
MEM-based media containing 15% FBS. Canine progenitor
epithelial keratinocytes (CPEKs, ZenBio, Research Triangle
Park, NC, USA) were grown in Epidermal Keratinocyte-
based media (ZenBio, Research Triangle Park, NC,  USA)
containing 10% FBS. Cytokines were purchased (canine
IFN-, R&D Systems, Minneapolis, MN,  USA) or generated
by our group (Gonzales et al., 2013) (canine IL-31). For
mitogen stimulation experiments, 50 ng/mL phorbol 12-
myristate 13-acetate (PMA, Sigma–Aldrich, St. Louis, MO,
USA) plus 2 M ionomycine (Sigma–Aldrich, St. Louis, MO,
USA), 100 ng/mL lipopolysaccharide (LPS, Sigma–Aldrich,
St. Louis, MO,  USA) or 5 g/mL concanavalin A (ConA,
Sigma–Aldrich, St. Louis, MO,  USA) were incubated with
PBMCs overnight at 37 ◦C. The following day supernatants
were collected and assessed for cytokine production.
2.3. ELISpot
PBMCs isolated from HDM-sensitized dogs were incu-
bated on pre-coated IFN- and IL-4 ELISpot plates (R&D
Systems, Minneapolis, MN,  USA) in AIM-V AlbuMax serum
free medium (Invitrogen, Grand Island, NY, USA) together
with 10 g/mL HDM antigen (Greer Laboratories, Lenoir,
NC, USA) for 24 h at 37 ◦C then removed by washing.
Biotinylated detection antibody was added and plates incu-
bated overnight at 4 ◦C. Alkaline phosphatase conjugated
streptavidin was then added followed by substrate. The
number of IFN- or IL-4 secreting cells (spots) was quanti-
ﬁed using an AID ELISpot reader (Autoimmun Diagnostika
GmbH, Strassberg, Germany).
2.4. IL-31
Isolated PBMCs were resuspended in RPMI-1640 com-
plete media containing 10% FBS and cultured in the
presence of HDM antigen at 10 g/mL and Staphylococcus
enterotoxin B (SEB) (Sigma–Aldrich, St. Louis, MO,  USA)
at 0.10 g/mL for 96 hours at 37 ◦C. A GyroLab sandwich
immunoassay was  used to quantitate canine IL-31 levels
in cell culture media supernatant as previously described
(Gonzales et al., 2013). For IL-31R chain Q-RT-PCR, RNA
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Table 1
Primer and probe sequences for of IL-31R and GAPDH (control).
Gene Reagent 5′–3′ sequence
IL-
31RA
Forward primer ATGGATGCTCCTTCTACTCTGTAAACT
Reverse primer CAGGAAATGTTCTCAGGCTTAGC
Probe AGCCTGGCAGTTCT
w
c
f
3
U
g
q
W
a
T
2
i
a
r
B
h
t
b
a
I
3
3
p
a
F
R
(
pGAPDH Forward primer GGCACAGTCAAGGCTGAGAAC
Reverse primer CCAGCATCACCCCATTTGAT
Probe TCCAGGAGCGAGATC
as isolated using the RNeasy Mini Kit (Qiagen, Valen-
ia, CA, USA) according to manufacturer’s instructions
rom cells treated with 10 ng/mL IFN- (to up-regulate IL-
1 receptor expression, R&D Systems Minneapolis, MN,
SA) and untreated controls or from frozen dorsal root
anglia disrupted using a mortar and pestle. RNA was
uantitated using a Nano Drop 8000 (Thermo Scientiﬁc,
altham, MA,  USA) and quality/integrity was assess using
 2100 Bioanalyzer (Agilent Technologies, Fort Worth,
X, USA). PCR reactions were run in a total volume of
0 L using 500 ng of RNA with the SuperScript III Plat-
num One-Step (Invitrogen, Grand Island, NY, USA) system
ccording to manufacturer’s instructions. Samples were
un on a 7900HT Fast Real-Time PCR System (Applied
iosystems, Foster City, CA, USA) and normalized to the
ousekeeping gene GAPDH (Saliaris et al., 2007). Rela-
ive quantitation was calculated by standard method. In
rief, the values used to express fold increase are gener-
ted by (2(ˆ-treatment Ct − control Ct)) where Ct = Ct
L-31RA − Ct GAPDH (Table 1).
. Results
.1. Allergen sensitization induces a Th2 polarized
henotype
PBMCs from allergen-sensitized dogs were collected
nd frozen at both pre- and post-HDM sensitization for
ig. 1. ELISpot analysis of IFN- and IL-4 production by PBMCs isolated from dogs
epresentative images from ELISpot wells from pre- (week −1) and post- (week 
week −1 and day 0) and after (weeks 5 and 7) sensitization each from a single in
ost-  (week 5) sensitization where n = 30.nd Immunopathology 157 (2014) 42– 48
simultaneous analysis of cytokine production in an ELISpot
assay using IFN- protein as an indicator of Th1 polariza-
tion and IL-4 protein as an indicator of Th2 polarization. The
dramatic increase in HDM-induced IL-4 production (Fig. 1A
and B) suggests that sensitization with HDM induces a Th2
phenotype. The alteration in polarization was  very consis-
tent (Fig. 1C and Supplementary Table 1) and repeatable in
two  entirely separate experiments.
Supplementary material related to this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
vetimm.2013.10.017.
3.2. Polarization of cells changes upon re-exposure to
allergen
In order to further characterize the polarization of
PBMCs collected from dogs chronically sensitized to aller-
gen, dogs were initially sensitized to allergen with three
injections two  weeks apart and then re-exposed to aller-
gen three more times at approximately 1 month intervals
after the initial sensitization regime (Fig. 2, arrows indicate
allergen exposure). After re-exposure, IL-4 remained ele-
vated and IFN- expression increased. Dogs then remained
unchallenged, and cytokine production was continually
measured. As time from challenge increased, the response
to allergen stimulation decreased for both IL-4 and IFN-
(Fig. 2 days 201 and 242). As may be expected based
on previous experimental data and clinical presentation,
re-challenge with allergen induced increased cytokine pro-
duction including IL-4 and interestingly IFN- as well (Fig. 2
day 291).
3.3. Th2 polarized cells produce IL-31 in response to
HDM and SEBIn order to identify which cell types may  be capable of
IL-31 production, naïve PBMCs were treated with a vari-
ety of immune stimulating agents including LPS, ConA, and
 pre- and post-HDM allergen sensitization showing Th2-polarization. (A)
5) sensitization are shown. (B) Analysis at two  independent times before
dividual is shown. (C) Average cytokine production pre- (week −1) and
E.E. McCandless et al. / Veterinary Immunology a
Fig. 2. Cytokine response to allergen stimulation of PBMCs over time
shown in days. Pre-sensitization time points are days 0 and 7. Arrowheads
indicate administration of allergen. Data from two  different individuals (A
and  B) are shown.
PMA  plus ionomycin, and cell supernatants were analyzed
for IL-31. The mitogen that induced the most IL-31 produc-
tion compared to any other treatment group tested was
PMA plus ionomycin (Fig. 3A).
To further characterize the cellular source of IL-31,
cells were collected both pre- and post-sensitization to
represent a Th1 and Th2 phenotype, respectively. Since
mitogen-activation of T cells can be considered artiﬁcial,
we wanted to build an ex vivo system relevant to assessing
a more natural scenario in which IL-31 may  be produced. To
accomplish this, we used the Th2-polarized (characterized
as above by expression of the Th2 representative cytokine
IL-4) HDM-speciﬁc PBMCs, and cultured them in the pres-
ence of HDM and/or Staphylococcus entertoxin B (SEB) and
found these conditions resulted in the synergistic produc-
tion of IL-31 (Fig. 3B).
3.4. Monocytic cells, keratinocytes, and neurons express
IL-31R˛Canine monocytic cells (DH82) where examined by
quantitative-real time PCR (Q-RT-PCR) for expression of the
IL-31R˛ chain. Although the IL-31R  ˛ mRNA was detectable
in naive cells, treatment with IFN- resulted in a 10-fold
Fig. 3. Treatment of normal PBMCs with various immunostimulants induces pr
cytokine. (B) IL-31 production is associated with allergen-sensitized Th2 polariz
indicates assay limit of IL-31 detection.nd Immunopathology 157 (2014) 42– 48 45
increase in IL-31R  ˛ message (Fig. 4A). Under resting con-
ditions, canine epidermal keratinocytes (CPEKs) had no
detectable IL-31R  ˛ mRNA (data not shown) but inter-
estingly activation with IFN- resulted in expression of
IL-31R  ˛ transcript (Fig. 4B). A relative comparison of
CPEK IL-31R  ˛ message levels indicates that under these
conditions, CPEKs (activated with IFN-) still express
approximately 3 log-fold less IL-31R  ˛ compared to inactiv-
ated monocytic cells (Fig. 4B). Q-RT-PCR analysis of DRG
tissue revealed expression of the IL-31R  ˛ in four healthy
dogs (Fig. 4B). Interestingly, the level of IL-31R  ˛ transcript
expressed by inactivated monocytic cells and DGR tissue is
remarkably similar (Fig. 4B).
4. Discussion
Atopic dermatitis is a multifactorial disease with
involvement of multiple tissues including a diverse range
of cell types and commonly associates with bacterial infec-
tions (DeBoer, 2004). Like many allergic conditions, AD
is characterized as a Th2 polarized disease (Marsella and
Girolomoni, 2009). Much of the previous work to date has
investigated the Th1 and Th2 hallmark cytokines including
IL-4 by evaluating messenger RNA in clinical samples and
in established models of canine allergy (Hayashiya et al.,
2002; Marsella et al., 2005, 2006). Data from the current
study is in agreement with previous reports of dogs with
AD having increased IL-4 mRNA levels (Hayashiya et al.,
2002; Nuttall et al., 2002b; Olivry et al., 1999) and builds
on this body of work with the demonstration of cytokine
protein levels increasing after sensitization to HDM, a com-
mon  canine allergen (Kim et al., 2011a; Masuda et al., 2000).
The Th2 polarization in this model is clear with almost
no IL-4 production pre-sensitization followed by a distinct
increase post-sensitization. Although a Th2 imbalance is
widely associated with atopic dermatitis there have been
reports of IFN- expression in lesional skin samples and
data suggesting that IFN- expression may  be associated
with a chronic disease state (Nuttall et al., 2002a; Olivry
et al., 1999), similarly to what is seen in the human disease
(Hamid et al., 1994; Thepen et al., 1996). Although our data
is generated using PBMCs as opposed to skin, it is consistent
with previous studies demonstrating increased IFN- pro-
duction during what may  be characterized as the chronic
oduction of IL-31. (A) Treatments show differential stimulation of IL-31
ed PBMCs and is increased upon HDM and SEB treatment. Dashed line
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cig. 4. Fold increase in IL-31 receptor expression as assessed by Q-RT-PCR
ith  IFN-. (B) Relative expression of IL-31R mRNA in keratinocyte pro
oot  ganglia (DRG) tissue compared to untreated DH82s where n = 3.
hase of the disease model. These results suggest that in
his model there is a clear Th2 response to allergen but also
nvolvement of Th1 cytokines and supports the hypothe-
is that IFN- is associated with a chronic disease state in
ogs.
Based on the ability of PMA  to activate protein kinase C
ownstream of the T cell receptor (Berry et al., 1989; Chatila
nd Geha, 1988) and the lack of IL-31 production from the
onocyte-activator LPS, the data in this study suggests that
anine T cells are a source of IL-31. Under more physi-
logically relevant conditions using PBMCs isolated from
DM-sensitized dogs, we have seen that IL-31 is produced
fter exposure of Th2 polarized cells to allergen and bacte-
ial endotoxin. The polarization status of the cells appears
o be an important characteristic associated with IL-31
roduction as cells collected from dogs pre-sensitization
ave signiﬁcantly reduced cytokine production compared
o post-sensitization. To conﬁrm polarized T cells as the
ource of IL-31, cell-type speciﬁc characterization along
ith isolation or intracellular labeling techniques within
he polarized PBMCs cultures would be needed. Concur-
ent staphylococcal infections are common in dogs with
topic dermatitis (DeBoer and Marsella, 2001) and col-
nization with Staphylococcus pseudintermedius is more
revalent in dogs with AD compared to healthy controls
Fazakerley et al., 2009). Staphylococcus aureus has been
hown to promote the production of Th2 cytokines by
BMCs from humans with AD (Dillon et al., 2004; Lin et al.,
011) including IL-31 (Niebuhr et al., 2011; Sonkoly et al.,
006). Importantly, recent studies have demonstrated that
L-31 is detected in dogs with AD but not non-diseased
nimals (Gonzales et al., 2013).
Based on the IFN- production we saw in the char-
cterization of the HDM allergen model over time, we
ere interested in further investigating the involvement
f this Th1 cytokine in a classically Th2 disease. The IL-31
eceptor has been characterized as heterodimic consist-
ng of the OSMR chain and the IL-31 receptor alpha chain
IL-31R˛) (Dillon et al., 2004). Studies have shown that
hile both receptor chains are required to induce signaling,
he IL-31R˛  has the predominant interaction with the
ytokine (Diveu et al., 2004). Data from the current study1R mRNA in monocytic cells (DH82) at six and 24 hours post-treatment
cells (CPEK) treated with IFN- (24 hours) and RNA isolated from dorsal
indicate that although the production of IL-31 came from
polarized cultures exhibiting a Th2-cell phenotype, the
ability to respond to the cytokine, i.e. receptor expres-
sion, may  depend at least in part on Th1 cytokine presence
since IFN- was  required to induce IL-31R˛  gene expres-
sion in cells. Additionally our results showed that IFN-
increased expression of the IL-31R˛, which is in agreement
with previous ﬁndings that IFN- can increase expres-
sion if the IL-31 receptor in human monocytes (Diveu
et al., 2003) and skin-resident cells including keratino-
cytes (Heise et al., 2009; Kasraie et al., 2011). Recent data
from our group conﬁrms that IFN- induced the pres-
ence of functional IL-31 receptor on canine monocytic
cells by causing IL-31-mediated phosphorylation of STAT3
and ERK1/2 (Gonzales et al., 2013). Although receptor
expression implicates both monocytes and keratinocytes
as having the potential ability to respond to IL-31, addi-
tional studies are needed to conﬁrm and identify the
physiological effect.
IL-31R˛ mRNA was also detected in DRG tissue. DRG
are neuronal cells involved in the transition of the pru-
ritic signal to the spinal cord (Buddenkotte and Steinhoff,
2010) and have been shown to express relatively high lev-
els of classically hematopoietic receptors including the H4
histamine receptor (Strakhova et al., 2009) as well as the
IL-31 receptor (Bando et al., 2006). These data imply that
neurons may  be able to directly respond to IL-31. There is
evidence to support an IL-31 mediated direct effect on neu-
ronal cells as exogenous administration of IL-31 induces
pruritus in dogs within two hours (Gonzales et al., 2013).
Although reports have shown upregulation of cytokines
and other inﬂammatory mediators post-treatment with
IL-31 (Cornelissen et al., 2012; Zhang et al., 2008), phys-
iological effects seen in such a short time frame may be the
result of direct neuronal action.
Taken together, these data suggest a dual-involvement
of both Th1 and Th2 cytokines in responses in canine
allergy. An important role for IL-31 in pruritus has been
suggested in human AD (Ezzat et al., 2011; Raap et al., 2008;
Sonkoly et al., 2006) and most recently characterized in
canine AD (Gonzales et al., 2013). Expression of the IL-31
receptor on not only monocytic cells, but also keratinocytes
nology aE.E. McCandless et al. / Veterinary Immu
and DRG tissue suggest that this cytokine may  mediate dia-
log between the immune system and the peripheral organ
sites. The results of the current study identify stimulated
Th2 polarized cells as a source of canine IL-31 and suggest
disease-relevant tissues as the target. This data builds on
growing understanding of the mechanism of action of IL-31
in canine AD and highlights the complexity and breadth of
action that this cytokine may  have in orchestrating cellu-
lar changes within the animal and inducing clinical signs
associated with allergic skin disease in dogs.
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